Home › Castration-Resistant Prostatic Cancer › Oregon
Castration-Resistant Prostatic Cancer clinical trials in Oregon
3 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Oregon.
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- VA Portland Health Care System, Portland
- Oregon Urology Institute, Springfield
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Oregon Urology Institute, Springfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.